Clinical Trial Search

Primary: Total Consumption of Fentanyl (in Micrograms) Self-administered by the Patient and Accessed at 24 and 48 Hours After Spine Surgery. — 726; 503; 180; 136 micrograms

Primary: Proportion of Patients Who Achieved ASAS20 Response in the Pooled Secukinumab Group Compared With the Placebo Group at Week 12 — 72; 31 Participants — p=0.3512

Primary: Fasting Glucose — 4.8; 5.0 mmol/L — p=0.327

Primary: Change From Baseline in Peak Respiratory Oxygen Uptake (VO2peak) Adjusted to Body Weight) After 3 Months of Treatment — 0.51; 0.19 mL/kg/min — p=0.2327

Primary: Percentage of Participants With Treatment-Emergent Sinus Bradycardia Events — 1.0; 1.9; 7.4; 7.8 Percentage of participants — p=0.026

Primary: Fasting Glucose — 5.1; 5.9 mmol/L — p=0.005

Primary: Montgomery Asberg Depression Rating Scale — 34 units on a scale

Primary: Change in Depression Severity (Measured by Montgomery Asberg Depression Rating Scale) — 25.26; 1.03; 13.78; 1.08 score on a scale — p=< 0.025

Primary: Patients Who Responded to Controlled Ovarian Hyperstimulation — 7; 5; 3; 5 Participants

Primary: Number of Participants With Treatment-Emergent Adverse Events (All Causalities) — 92; 152; 244; 18 Participants

Primary: Post-operative Pain — 5.47; 4.47; 4.00; 4.28 score on a scale — p=0.24

Primary: Change in Investigator's Global Assessment Grade — -0.8 units on a scale

Primary: Plasmatic Glucose Levels (mg/dl). — 80; 82; 114; 111 mg/dl — p=0.38

Primary: Numerical Rating Scale (NRS) Post-operative Pain Score on Post-Operative Day 1 (POD1). — 4.17; 4.97 units on a scale

Primary: Percentage of Participants With Local Reactions Within 7 Days After Vaccination 1 — 19.7; 16.9; 17.7; 12.8 percentage of participants